Pfizer targets new weight loss medication market with billion-dollar purchase

Pfizer’s $5 Billion Acquisition of Methosera

It’s been more than five months since Pfizer halted the development of a weight loss drug, Danuglipron. On Monday, the company announced plans to purchase the biopharmaceutical firm Methosera for close to $5 billion.

In a recent press release, Pfizer confirmed a unanimous decision to acquire Methosera, which is described as a “clinical stage biopharmaceutical company focused on advancing next-generation treatments for obesity and cardiac metabolic diseases.”

“Obesity is a broad and growing concern, linked to over 200 health issues,” the announcement highlighted.

The agreement will see Pfizer acquire all outstanding shares at $47.50 each, amounting to about $4.9 billion in total valuation.

Interestingly, it was reported that there are currently no obesity drugs available on the market following this announcement.

The portfolio from Methosera includes drug trials at various stages, notably “two oral GLP-1 RA candidates” which are expected to enter clinical trials soon.

Bernard, co-founder and CEO of Methosera, expressed that since its inception in 2022, the company has been diligently working to alleviate the physical, emotional, and financial challenges of obesity with a range of innovative hormone therapy candidates.

Curiously, in their press release, neither firm touched on well-known weight loss strategies, such as calorie deficit diets or regular exercise, as integral parts of a healthy lifestyle. Attempts to clarify their positions on these traditional methods went unanswered from both Pfizer and Methosera.

There’s certainly big money in the development of weight loss drugs. A recent article suggested that Novo Nordisk, a major player in the obesity treatment market with drugs like Wegovy and Ozempic, could achieve a $1 trillion valuation by 2030.

With such staggering numbers, one has to wonder: Is a drug really the solution? Robert Kennedy, Secretary of Health and Human Services, commented on the hype surrounding Novo Nordisk’s products, saying, “With those figures, we seem to overlook underlying causes.”